Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ObjectiveCD8+ T cells are the key effector cells in the anti-tumor immune response. The mechanism underlying the infiltration of CD8+ T cells in esophageal squamous cell carcinoma (ESCC) has not been clearly elucidated. MethodsFresh ESCC tissues were collected and grouped according to the infiltration density of CD8+ T cells. After the transcriptome sequencing on these samples and the combined analyses with The Cancer Genome Atlas (TCGA) ESCC data, a secreted protein DEFB1 was selected to explore its potential role in the infiltration of CD8+ T cells. Bioinformatics analyses, histological verification and in vitro experiments were then performed. ResultsDEFB1 was highly expressed in ESCC, and the high expression of DEFB1 was an independent risk factor for overall survival. Since the up-regulation or down-regulation of DEFB1 did not affect the proliferation, migration and apoptosis of ESCC cells, we speculated that the oncogenic effect of DEFB1 was achieved by regulating microenvironmental characteristics. Bioinformatics analyses suggested that DEFB1 might play a major role in the inflammatory response and anti-tumor immune response, and correlate to the infiltration of immature dendritic cell (imDC) in ESCC. Histological analyses further confirmed that there were less CD8+ T cells infiltrated, less CD83+ mature DC (mDC) infiltrated and more CD1a+ imDC infiltrated in those ESCC samples with high expression of DEFB1. After the treatment with recombinant DEFB1 protein, the maturation of DC was hindered significantly, followed by the impairment of the killing effects of T cells in both 2D and 3D culture in vitro. ConclusionsTumor-derived DEFB1 can inhibit the maturation of DC and weaken the function of CD8+ T cells, accounting for the immune tolerance in ESCC. The role of DEFB1 in ESCC deserves further exploration.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+ T cell function in esophageal squamous cell carcinoma
- Date Crossref
- 01/01/2024
- Éditeur
- Chinese Journal of Cancer Research
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tianjin Medical University Cancer Institute and Hospital pays non établi dans la noticeÉtablissement de santé
-
Chinese PLA General Hospital Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Sinovac Biotech pays non établi dans la noticeEntreprise
-
Southern University of Science and Technology Department of Biotherapy Center pays non établi dans la noticeUniversité ou école supérieure
-
Shenzhen Second People's Hospital pays non établi dans la noticeÉtablissement de santé
-
LTD. Beijing DCTY Biotech CO. pays non établi dans la noticeEntreprise
Tianjin Medical University Cancer Institute and Hospital, Department of Oncology — Chinese PLA General Hospital et Sinovac Biotech, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.